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https://doi.org/10.1016/j.stemcr.2020.06.020SUMMARYEstrogen-receptor-positive breast tumors are treatedwith anti-estrogen (AE) therapies but frequently develop resistance. Cancer stem cells
(CSCs) with high aldehyde dehydrogenase activity (ALDH+ cells) are enriched following AE treatment. Here, we show that the inter-
leukin-1b (IL-1b) signaling pathway is activated in ALDH+ cells, and data from single cells reveals that AE treatment selects for IL-1 recep-
tor (IL1R1)-expressing ALDH+ cells. Importantly, CSC activity is reduced by an IL1R1 inhibitor in AE-resistant models. Moreover, IL1R1
expression is increased in the tumors of patients treated with AE therapy and predicts treatment failure. Single-cell gene expression anal-
ysis revealed that at least two subpopulations exist within the ALDH+ population, one proliferative and one quiescent. Following AE ther-
apy the quiescent population is expanded, which suggests CSC dormancy as an adaptive strategy that facilitates treatment resistance.
Targeting of ALDH+IL1R1+ cells merits testing as a strategy to combat AE resistance in patients with residual disease.INTRODUCTION
Breast cancer (BC) represents 25% of all cancer diagnoses
and is the fifth most common cause of death in women
worldwide. Approximately 80% of BCs are positive for es-
trogen receptor expression (ER+ tumors) and are treated
with anti-estrogen (AE) adjuvant therapies such as tamox-
ifen or fulvestrant. Despite the clear benefit of these drugs
at reducing tumor recurrence, de novo or acquired resistance
often occurs (Pan et al., 2017).
Cancer stem cells (CSCs) are a cellular population en-
dowed with self-renewal properties, which are responsible
for tumor progression and metastasis (Reya et al., 2001).
Aldehyde dehydrogenase (ALDH) activity is reported to
be a CSC marker in human BC cells (Ginestier et al.,
2007). ALDH+ cells are ER-negative and likely to be resistant
to the direct effects of AE therapy (Honeth et al., 2014). We
have previously established that ALDH+ cells drive thera-
peutic resistance in ER+ BC tumors (Simo˜es et al., 2015).
Intra-tumor heterogeneity within BCs hinders accurate
diagnosis and effective treatment. Understanding of the
cellular diversity within the CSC population, especially at
the single-cell level, is limited. Given the importance of
ALDH+ cells in promoting AE resistance, we investigated
the gene expression pattern of this cellular population at
the single-cell level. This study reveals a previously unchar-
acterized level of heterogeneity within AE-resistant CSCs
and identifies IL1R1 as a potential target in refractory and
dormant BCs.Stem Cell
This is an open access artiRESULTS
ALDH+ Cells from AE-Treated ER+ BCs Have Greater
Breast CSC Activity Than ALDH Cells
Previous research reported by our group (Simo˜es et al.,
2015) established that AE treatment of BC patient-derived
xenograft tumors in mice enriches for breast CSCs (BCSCs)
with high ALDH enzymatic activity. To further investigate
this AE-resistant population, we isolated ALDH+ and
ALDH cells from eight metastatic ER+ BCs undergoing
AE therapies. There was significant inter-individual varia-
tion in the percentage of ALDH+ cells (range 0.32%–
27.3%) (Figures 1A and S1A). Importantly, ALDH+ cells ex-
hibited significantly greater BCSC activity as assessed by
mammosphere formation than ALDH cells in seven out
of eight patient samples, and in four of these samples the
mammosphere-forming efficiency (MFE) was increased by
more than 3-fold (Figure 1B). On average, ALDH+ cells
from the eight metastatic BC samples showed 3.8-fold
greater MFE than ALDH cells (p = 0.001) (Figure 1C).
Next, we investigated the in vivo tumor-initiating capabil-
ities of ALDH+ cells isolated from the ER+ cell line MCF-7
following 6-day in vitro treatment with the AEs tamoxifen
or fulvestrant (Figure 1D). Injection of 1,000 ALDH+ cells
consistently gave rise to bigger tumors compared with the
same number of ALDH cells, significantly so in tamox-
ifen- and fulvestrant-treated cells (Figure 1E). Extreme
limiting dilution analysis revealed that on average the
number of tumor-initiating cells was 4.2-fold higher inReports j Vol. 15 j 307–316 j August 11, 2020 j ª 2020 The Authors. 307
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Figure 1. AE-Treated ALDH+ Cells from ER+ BC Cells Have Greater BCSC Activity Than ALDH Cells In Vitro and In Vivo
(A) Representative fluorescence activated cell sorting (FACS) plot showing the ALDH+ population identified through the Aldefluor assay for
an individual patient sample. ALDH+ cells (red gate) were discriminated from ALDH cells using the diethylaminobenzaldehyde (DEAB)
control.
(B) Bar chart shows mammosphere-forming efficiency (MFE) percentage of ALDH+ cells (red) and ALDH cells (blue) from ER+ metastatic
BCs undergoing AE therapies.
(C) Bar chart illustrates fold change in MFE percentage between ALDH+ and ALDH cells across eight different patient samples.
(D) Schematic overview of the in vivo transplantation assay to test tumor formation capacity between ALDH+ and ALDHMCF-7 cells. MCF-7 cells
were pre-treated in vitro for 6 days with control (ethanol), tamoxifen (1 mM) or fulvestrant (0.1 mM) followed by the Aldefluor assay. ALDH+ and
ALDH cells were FACS sorted, counted using trypan blue, and engrafted into the left and right flank, respectively, of the same NSG mice.
(E) Averaged tumor growth from control (pink; left panel), tamoxifen (green; middle panel), or fulvestrant-treated (blue; right panel)
cells. 1,000 ALDH+ (hollow circles) and 1,000 ALDH (filled circles) cells are represented. *p% 0.05 (two-tail, two-sample equal-variance t
test). Number of mice per condition = 4 (vehicle-treated mice, n = 3). Data shown as mean ± SEM.
(F) Table shows extreme limiting dilution analysis from in vivo injections of ALDH+ and ALDH cells (10,000; 1,000; 100 cells) to assess
tumor-initiating cell frequency. Tumor growth was assessed at week 20 and is represented as mice positive for growth/mice tested for each
cell number.
See also Figure S1.ALDH+ compared with the non-BCSC ALDH cells in all
three conditions tested (Figure 1F). As few as 100 ALDH+
cells gave rise to tumors in mice whereas 100 ALDH cells
failed to do so. These results highlight the increased tu-
mor-initiating capabilities of the ALDH+ population in
comparison with ALDH cells, implying the need to char-
acterize this population of CSCs that survive AE therapies.308 Stem Cell Reports j Vol. 15 j 307–316 j August 11, 2020Transcriptomic Characterization of ALDH+ Cells in
Therapy-Resistant Patient Samples
To better understand the development of resistance to AE
therapies in ER+ BC patients, we interrogated and
compared the gene expression pattern between ALDH+
andALDH cells innineER+metastatic samples (Figure 2A).
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Figure 2. ALDH+ Cells from ER+ Metastatic Samples Show a Distinct Gene Expression Pattern Compared with ALDH Cells
(A) Heatmap illustrating the 599 differentially expressed genes (447 up, 152 down) between ALDH+ and ALDH cells (red color shows gene
upregulation, green shows downregulation in ALDH+ relative to ALDH cells identified by pairwise rank products with a threshold
probability of false positives <0.05) from metastatic ER+ patient BCs.
(B) Gene expression fold change (FC) between ALDH+ and ALDH cells of 18 ALDH isoforms detected in the Affymetrix array data. Mean FC
for all metastatic samples (n = 9) is represented for each isoform. Red bar indicates isoforms with FC higher than 2.
(C) qPCR analysis of ALDH1A1 and ALDH1A3 gene expression in the nine patient metastatic samples that were used in the Affymetrix array.
Data are shown as log10 FC between ALDH
+ and ALDH cells. Mean linear FC of the two ALDH isoforms for all samples is shown.
(D) A stably transduced inducible shALDH1A3 MCF-7 cell line was treated with control, tamoxifen (TAM), or fulvestrant (FULV) for 6 days
concomitantly with (filled pattern) or without (solid bars) doxycycline (DOX). ALDH1A3 mRNA levels were examined by qPCR (left) and
percentage of ALDH+ cells was assessed using the Aldefluor assay (right). Data of at least three independent experiments are shown (*p <
0.05, **p < 0.01, ***p < 0.001).
(E) Venn diagram illustrates meta-analysis of the MCF-7 cell line (control, tamoxifen, fulvestrant-treated ALDH+ versus ALDH cells) and
the patient Affymetrix data (ALDH+ versus ALDH cells). iPathway guide software tool (AdvaitaBio) was used to plot the diagrams. The red
dashed-line box indicates the 100 genes that are commonly differentially expressed in ALDH+ cells of patient samples and MCF-7 cell line.
The log2 FC cutoff applied to the ALDH
+ versus ALDH cells obtained from the meta-analysis data was 0.6.
(legend continued on next page)
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pleural effusion or ascitic drainage as palliative care, but
while six samples were treated with endocrine therapies
the other three were endocrine therapy-naive (Table S1).
Overall, 599 geneswere found to be differentially expressed
(p% 0.05) between the two ALDH cell populations among
the 18,752 genes with measured expression (Table S2).
To identify which isoforms of ALDH are responsible for
the Aldefluor activity of ALDH+ cells in metastatic ER+ pa-
tient samples, we investigated the mRNA expression levels
of the 18 detected ALDH isoforms in our patient sample da-
taset. ALDH1A1 and ALDH1A3 showed the greatest fold
change (FC) between ALDH+ and ALDH cells with a
mean FC higher than 2 (Figure 2B). Validation by qRT-
PCR confirmed the elevated expression of ALDH1A1 and
ALDH1A3 isoforms in the ALDH+ compared with ALDH
population, with a considerably higher averaged linear
FC of ALDH1A3 (300-fold) than ALDH1A1 (19-fold) across
the nine patient samples (Figure 2C). Interestingly, we also
found that 6 days of AE treatment significantly upregulated
ALDH1A3 mRNA levels in two ER+ cell lines, MCF-7 and
T47D (Figure S2A). Therefore, we used a doxycycline-
inducible short-hairpin RNA system to test the effects of
ALDH1A3 silencing on AE resistance. ALDH1A3 was stably
downregulated by 58% comparedwith transfected cells not
exposed to doxycycline, and there was a significant
decrease in the induction of ALDH1A3 mRNA levels
following AE treatment in the knockdown (KD) cells (Fig-
ure 2D, left). The enrichment in the ALDH+ cell population
after tamoxifen and fulvestrant treatments was signifi-
cantly reduced in the ALDH1A3 KD cells (Figure 2D, right),
indicating the importance of the ALDH1A3 isoform in
ALDH+ cell population after AE therapy.
We also interrogated the gene expression profile of
ALDH+ and ALDH populations from AE-treated MCF-7
cells. The meta-analysis from the patient and cell line mi-
croarray datasets (FC R ±1.5 and p % 0.05) revealed 100
genes commonly shared between ALDH+ cells of patient
samples and ALDH+ cells of the MCF-7 cell line (Figure 2E
and Table S3). Ingenuity Pathway Analysis for these genes
predicted activation of eight upstream regulators (Z score
R2.5), including several cytokines; for example, inter-
leukin-1b (IL-1b) (Figure S2B). Of the 100 genes identified
in the ALDH+ cell population, 15 were predicted to be regu-
lated by IL-1b and these were all upregulated in the ALDH+
cells, which is consistent with activation of IL-1b signaling
(Figure 2F). This activationwasmore obvious in the ALDH+
cells of AE-resistant samples, since 14 out of the 15 IL-
1b-regulated genes were expressed at lower levels in the(F) Ingenuity Pathway Analysis diagram showing that IL-1b sign
cell population. Straight arrows indicate network of 15 genes, predicte
cells.
See also Figure S2.
310 Stem Cell Reports j Vol. 15 j 307–316 j August 11, 2020ALDH+ cells of the endocrine therapy-naive samples (Fig-
ure S2C). One of these genes was interleukin-1 receptor
type 1 (IL1R1), which binds and transmits the signal of
both IL-1a and IL-1b.
AE Treatment Selects for IL1R1-Expressing ALDH+
Cells
To study the effects of AE treatment on the ALDH+ popula-
tion at the single-cell level, we analyzed the expression of
IL1R1 and ALDH1A3 in 178 individual ALDH+ cells
following tamoxifen or fulvestrant treatment. Sorted
ALDH+ cells were injected and captured in the C1 system,
followed by microscopic examination of cell singlets (Fig-
ure S3A). When comparing IL1R1 gene expression profiles
between control and AE-treated ALDH+ cells, we observed
that gene expression levels of IL1R1 increased significantly
following tamoxifen and fulvestrant treatment (Figures 3A
and 3B). In contrast, ALDH1A3 expression was high in
nearly all ALDH+ cells, with or without therapy, as expected
(Figures 3A and 3B). IL1R1 gene expression density plots re-
vealed that control ALDH+ cells match a bimodal distribu-
tion with two distinct transcriptomic states: a population
that comprises the majority of cells, which show none or
very low IL1R1 gene expression levels, and a small popula-
tion of cells showing high IL1R1 levels. However, following
AE therapy the vast majority of ALDH+ cells show high
IL1R1 gene expression levels (Figures 3B and S3B). These re-
sults reveal the existence of cellular diversity within the
ALDH+ population that can be unraveled by single-cell
gene expression profiling, and highlight IL1R1 as an impor-
tant gene in AE-resistant BCSCs. Indeed,MCF-7 tamoxifen-
and fulvestrant-resistant cell sublines express significantly
higher levels of both ALDH1A3 and IL1R1 genes when
compared with parental cell sublines (Figure 3C; Coser
et al., 2009). In addition, AE-resistant MCF-7 cell lines
show increased MFE when compared with the parental
AE-sensitive cell line, which can be significantly reduced
by anakinra, a recombinant form of human IL1R1 antago-
nist (Figure 3D).
To determine the clinical significance of identifying
IL1R1 as facilitating AE resistance, we assessed IL1R1 gene
expression levels in patient breast tumors. Consistent
with our cell line data, we found IL1R1 gene expression
levels to be increased in breast tumors following short-
term administration of fulvestrant to patients (Figure 3E;
Patani et al., 2014). In addition, we observed that IL1R1
expression was significantly increased upon short- and
long-term aromatase inhibitor (AI) treatment comparedaling is predicted to be activated (orange color) in the ALDH+
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with baseline levels in four different patient cohorts
totaling 404 patients (Dunbier et al., 2013; Ellis et al.,
2017; Turnbull et al., 2015) (Figure 3F). Notably, we also
found that elevated expression of IL1R1 in ER+ patients
who had been treated with AI for 2 weeks was significantly
associated with a poor outcome (Figure 3G).
Single-Cell RNA Profiling Identifies a Dormant ALDH+
Population that Is Expanded after AE Treatment
IL1R1 and ALDH1A3 single-cell gene expression revealed
heterogeneity within ALDH+ cells; therefore, we decided
to investigate the existence of putative subpopulations
within the ALDH+ cell population. We examined the
mRNA expression level of 68 genes across 377 single
ALDH+MCF-7 cells following control, tamoxifen, or fulves-
trant treatment. The 68-gene list (see Supplemental Exper-
imental Procedures) comprised key regulators associated
with stemness, self-renewal pathways, and markers related
to ALDH+ cells that were identified in the whole gene
expression dataset (Figure 2). A Gaussian mixture model
approach to estimate and assign clusters to the cells pre-
dicted the existence of seven different cellular ALDH+ pop-
ulations (control: 1 and 2, tamoxifen: 3 and 4, fulvestrant:
5, 6, and 7) (Figure 4A). Some of these initial clusters were
merged, based on their gene expression similarities using
Ward’s hierarchical clustering on Euclidean distance
coupled with bootstrapping to estimate branch robustness.
This analysis resulted in two major populations of cells,
population A and population B, which were both made
of clusters from the three different treatments, and a small
population of fulvestrant-treated cells (fulvestrant 7) thatFigure 3. Single ALDH+ Cell Gene Expression in the MCF-7 Cell Lin
(A) Heatmap of the relative expression across single ALDH+ cells (co
treatment, i.e., control (left), tamoxifen (middle), and fulvestrant (rig
(blue).
(B) Density plots of gene expression in all single ALDH+ cells analyze
(C) Box plots and scatterplots show ALDH1A3 and IL1R1 relative gene
compared with tamoxifen-resistant (TAMR, n = 4) and fulvestrant-resi
from sublines grown without drugs (MCF-7 parental and TAMR) or wit
calculated with Wilcoxon test, **p < 0.01.
(D) MCF-7 parental, tamoxifen-resistant (TAMR), and fulvestrant-res
anakinra or vehicle control in the presence of 10 ng/mL IL-1b for 72 h
± SEM of three experiments with at least three technical replicates e
(E) Box plot and scatterplot show IL1R1 expression from ER+ BC after p
high-dose, 500 mg) compared with IL1R1 expression before treatmen
sample is displayed as a blue (downregulation) or red (upregulation)
(F) Box plot and scatterplot show IL1R1 log2 FC gene expression in thre
(3m) of letrozole (Let, Edinburgh dataset), anastrozole (Ana, Royal M
pre-treatment levels. Each patient sample is displayed as a blue (dow
paired Wilcoxon test.
(G) Kaplan-Meier curves represent BC specific-survival (BCS) for IL1R1
who received 2 weeks of AI treatment. p value is based on a log-rank
See also Figure S3.
312 Stem Cell Reports j Vol. 15 j 307–316 j August 11, 2020were distinct from the rest of the cells (Figure 4B). Next,
we applied discriminant analysis of principal components
(DAPC) to create a graphical representation of these three
distinct populations (Figure 4C). The eight genes most
associatedwith the first linear discriminant had the highest
contribution to the separation of population B from the
other populations (Figure 4D). Genes associated with cell
proliferation, for example the cycle regulator CCND1 and
protein kinase AKT1, were downregulated in population
B compared with population A, whereas the expression of
the mesenchymal marker SNAI2 was higher in the former
(Figure 4E). Moreover, population A, which comprised
the vast majority of the ALDH+ cells analyzed (82%), ex-
hibited higher expression of proliferative markers PCNA
and KI67 in comparison with population B (Figure S4A).
Interestingly, only 10% of the non-treated ALDH+ cells be-
longed to the quiescent population B; however, following
tamoxifen and fulvestrant treatment the percentage of
quiescent cells represented 44% and 19% of the total cells,
respectively (Figure 4F). A recent study (Selli et al., 2019)
investigated gene expression changes of dormant and ac-
quired resistant ER+ tumors treated with an AI for more
than 4 months. Notably, ALDH1A1 and ALDH1A3 gene
expression levels were significantly increased in dormant
tumors compared with acquired resistant tumors, which
supports the existence of an ALDH+ dormant population
after AE treatment (Figure 4G). Relative to pre-treatment,
the dormant tumors also had significantly increased
expression of both ALDH1A1 and ALDH1A3 as well as
IL1R1 and SNAI2, along with reduced CCND1 (Figure S4B),
consistent with the results above for the dormante Identifies IL1R1 Overexpression Following AE Treatment
lumns) for ALDH1A3 and IL1R1 genes (rows). Cells are ordered by
ht). Colors represent expression levels from highest (red) to lowest
d from the two different AE treatments and control.
expression from MCF-7 parental/unselected clonal sublines (n = 7)
stant (FULVR, n = 4) clonal sublines (GEO: GSE14986 dataset). Data
h fulvestrant (FULVR). p value for at least four biological replicates
istant (FULVR) cells were pre-treated in adherence with 10 mg/mL
. MFE was assessed after pre-treatments. Data are presented as mean
ach. **p < 0.01.
re-surgical 4-week treatment with fulvestrant (low-dose, 250 mg or
t (Patani et al., 2014). Data are presented as log2 FC. Each patient
circle. p value calculated with paired Wilcoxon test.
e different patient cohorts in response to 2 weeks (2w) or 3 months
arsden dataset), and AI (Baylor dataset) treatment compared with
nregulation) or red (upregulation) circle. p value calculated with
-high and IL1R1-low of a cohort of 54 ER+ BC patients (Edinburgh)
test.
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Figure 4. Single-Cell Gene Expression Data Reveal a Dormant ALDH+ Population
(A) Scatterplot of the two first linear discriminants from discriminant analysis of DAPC analysis for 377 single ALDH+ MCF-7 cells using as
classifier the clusters identified through Mclust. The scatterplot shows the cluster of individual ALDH+ cells (rhomboids: control group;
circle: tamoxifen group; triangles: fulvestrant group). Control-treated ALDH+ cells (gray) clustered within two groups (clusters 1 and 2),
(legend continued on next page)
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population identified by single-cell analysis. These data
suggest that AE resistance can be driven by non-prolifera-
tive dormant ALDH+ cells and support a potential role for
IL1R1-targeted therapy to overcome resistance in ER+ BCs
(Figure 4H).DISCUSSION
Previously, we reported that ALDH+ cells are resistant to AE
therapy and that high ALDH1 expression predicts resis-
tance in women treated with tamoxifen (Simo˜es et al.,
2015). Our findings here establish a role for the IL1R1
signaling pathway in the regulation of AE-resistant
ALDH+ BCSCs. We also identify heterogeneity in the
ALDH+ cell population and an expansion of a quiescent
ALDH+ subpopulation after AE therapies.
Firstly, we showed that BC cells contain a population of
ALDH+ cells that survive AE treatments, which maintain
higher mammosphere-forming and tumor-initiating cell
frequency than ALDH cells. We next wanted to further
characterize these cells and the mechanisms that drive
them. ALDH1A1 and ALDH1A3 isoforms are both reported
to be predictive biomarkers of poor clinical outcome in BC
(Liu et al., 2014; Marcato et al., 2011), and we found them
to be the most highly increased among 18 ALDH isoforms
detected in metastatic patient-derived ALDH+ BC cells.
ALDH1A3 KD confirmed that this isoform is crucial for en-
riching the ALDH+ population following AE treatment.
These data support the growing body of literature
describing the involvement of ALDH1A3 in cancer stem-
ness, tumor progression, and poor prognosis.
We found that ALDH+ cells have a different gene expres-
sion profile compared with ALDH cells in both ER+ meta-Tamoxifen-treated ALDH+ cells (blue) also clustered within two grou
clustered within three groups (clusters 5, 6, and 7). Pooled data of t
(B) Ward hierarchical clustering of cell clusters using Euclidean distanc
of >0.90 indicating that these clusters are robust, thus identifying th
box) and population B (pink box) and a smaller one corresponding to
(C) Scatterplot of the DAPC analysis for single ALDH+ MCF-7 cells afte
discriminant 1 accounts for most of the differences between populat
(D) Distribution of the gene importance to build linear discriminants
labeled.
(E) Heatmap of relative gene expression across the three ALDH+ popu
important genes in the separation between population B and the oth
(blue).
(F) Bar charts show the percentage contribution of each ALDH+ subpo
fulvestrant.
(G) Box plots and scatterplots show ALDH1A1 and ALDH1A3 expression
neoadjuvant treatment with letrozole compared with expression befor
patient sample is displayed as a blue (downregulation) or red (upreg
(H) Diagram showing that AE therapies do not target ALDH+ cells and
See also Figure S4.
314 Stem Cell Reports j Vol. 15 j 307–316 j August 11, 2020static patient samples and MCF-7 cells. In particular, genes
that predicted activation of pro-inflammatory cytokine IL-
1b signaling, including IL1R1, were expressed at higher
levels in ALDH+ cells. Furthermore, these genes were ex-
pressed at even higher levels in ALDH+ cells of AE-treated
compared with AE-naive patient samples. Gene expression
analysis of ALDH+ cells from AE-sensitive primary BC sam-
ples would validate our findings further but was not possible
in the present study. By using single-cell gene expression
profiling in the ALDH+ cell population, we confirmed
IL1R1 to be significantly upregulated in AE-treated ALDH+
cells compared with control cells. Moreover, AE-resistant
cell lines express higher levels of IL1R1 and display enriched
CSC activity that is mainly dependent on IL-1b signaling,
since it is significantly reduced by IL1R1 inhibition. Impor-
tantly, we found that expression of IL1R1 is induced in the
tumors of patients treated with AE therapies and predicts
treatment failure. These data indicate that IL-1b signaling
is likely to be important for CSCs to drive AE resistance in
BC. IL1b expression correlates with increased aggressiveness
and enhancedmetastatic potential of BCcells, suggesting IL-
1b as a potential biomarker for predicting which patients are
likely to be diagnosed with BC metastasis, specifically to
bone (Tulotta et al., 2019). Indeed, our group has recently
demonstrated the importance of IL-1b-IL1R signaling in
regulating stem cell activity in BC metastasis to the bone
(Eyre et al., 2019).We established that bonemarrow-derived
IL-1b stimulates breast CSC colonization in the bone by
inducing intracellular nuclear factor kB and Wnt signaling
in breast CSCs. These findings suggest that metastatic
dissemination is selecting for IL1R+ CSCs that colonize the
IL-1b-producing bone marrow.
Single-cell targeted transcriptome analysis revealed the
existence of distinct clusters within ALDH+ cells and theps (clusters 3 and 4), and fulvestrant-treated ALDH+ cells (green)
hree independent experiments are shown.
e of all the genes. Boxes represent clusters with an unbiased p value
ree groups of cells: two major ones, renamed as population A (blue
Fulvestrant-7 (green box).
r treatment using as classifier the clusters identified in (B). Linear
ion B and the other two.
1 and 2. Genes above threshold 0.05 of linear discriminant 1 are
lations identified (A, B, fulvestrant 7 [fulv-7]) for the eight most
ers. Colors represent expression levels from highest (red) to lowest
pulation within the ALDH+ cells treated with control, tamoxifen, or
from ER+ dormant and acquired resistant tumors after 4 months of
e treatment (Selli et al., 2019). Data are presented as log2 FC. Each
ulation) circle. p value calculated with paired Wilcoxon test.
enrich for a dormant IL1R1+ALDH+ cell population.
expansion of a quiescent ALDH+ population (population B)
after AE therapies. Heterogeneity within BCSCs of MCF-7
cells has previously been described using different CSC
functional assays, such as mammospheres, growth in hyp-
oxia, and PKH26 retention, to isolate single cells for gene
expression analysis (Akrap et al., 2016). Our data suggest
that population B represents a small population of non-
dividing quiescent ALDH+ cells that survive AE treatments,
which may enable them to survive for long periods of time
and eventually lead to late recurrence in ER+ BC patients.
This idea is supported by data fromAI-induced dormant tu-
mors that express increased levels of ALDH1A1 and
ALDH1A3 genes. Recently, single-cell RNA profiling of
normal breast samples identified four cell clusters within
the ALDH+ cell population (Colacino et al., 2018). Interest-
ingly, population B resembles cluster 3 identified in this
publication, which was characterized by high expression
of mesenchymal markers, including SNAI2, and low
expression of proliferative genes, such as KI67, PCNA, and
CCND1. Population B expresses low levels of AKT1, and
AKT1low cancer cells have been reported to be quiescent
cells that survive chemotherapy in breast tumors (Kabraji
et al., 2017).
Combination therapies targeting both bulk tumor cells
and BCSCs should reduce the probability of tumor relapse;
therefore, pharmacological inhibitors that target CSCpath-
ways have been highly pursued and are being tested in pa-
tients (Brooks et al., 2015). In our model, both proliferative
and dormant AE-resistant BCSCs express IL1R1. This sug-
gests that anti-IL1R1 therapies, such as anakinra or canaki-
numab (human anti-IL-1b monoclonal antibody), could
represent a new strategy to target AE-resistant CSCs.
In conclusion, the presentwork contributes to our under-
standing of the cellular heterogeneity present in the AE-
resistant BCSC population. Our work suggests that CSC
dormancy is an adaptive strategy to evade AE treatments
and supports the targeting of ALDH+IL1R1+ cells to reverse
AE resistance. This work highlights the advantages of sin-
gle-cell transcriptomic analysis, rather than bulk tissue, to
interrogate the cellular heterogeneity within the ALDH+
CSC population. Further understanding of the dormant
ALDH+ population that survives AE therapies, particularly
using clinical samples, will provide new insights for pre-
vention and treatment of recurrences of ER+ BC.EXPERIMENTAL PROCEDURES
A comprehensive description of the methodology is included in
Supplemental Information.
Breast Cancer Samples
Consented, de-identified pleural effusion or ascitic fluids were
collected at the Christie NHS Foundation Trust (UK) or the Univer-sity of Michigan (USA). The clinicopathological details of the sam-
ples are shown in Table S4.
ALDH+/ Cell Isolation
BC cells were stained using the Aldefluor assay (STEMCELL Tech-
nologies) following themanufacturer’s protocol and isolated using
the Influx cell sorter (BD Biosciences).
Single-Cell Capture and Transcriptomics Profiling
Single ALDH+ MCF-7 cells were captured within the C1 system us-
ing the medium C1 Single-Cell Preamp Integrated Fluidic Circuit
(IFC, 10–17 mm) chips (Fluidigm, 100-5480). Individual cells
were visualized using the Leica Widefield Low Light microscope.
Cell loading, lysis, reverse transcription, and cDNA pre-amplifica-
tion were performed within the C1 system following themanufac-
turer’s instructions.We undertook three independent experiments
that resulted in the single-cell transcriptomics profiling of 377 sin-
gle cells. Data were acquired using the 96.96 Dynamic Array IFC
Biomark chips (Biomark HD Real-Time PCR System, Fluidigm) to
interrogate the expression of 68 TaqMan assays in each cell. Data
analyses included different quality control steps and two iterative
runs of clustering to identify cell populations. Further details on
experimental design and data processing are described in the Sin-
gle-Cell Data Analysis section of Supplemental Experimental
Procedures.
Data and Code Availability
The Affymetrix data have been deposited in NCBI’s Gene Expres-
sion Omnibus repository under series accession number GEO:
GSE136287.
SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/
10.1016/j.stemcr.2020.06.020.
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